Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | THRB | P10828 | 1/20 | 0.68 |
| ▸ | CNR1 | P21554 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | FAAH | O00519 | 2/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | DGKA | P23743 | 1/20 | 0.58 |
| ▸ | F7 | P08709 | 3/20 | 0.58 |
| ▸ | F3 | P13726 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | PPARG | P37231 | 2/20 | 0.58 |
| ▸ | PPARD | Q03181 | 2/20 | 0.58 |
| ▸ | PPARA | Q07869 | 2/20 | 0.58 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17558128 | 1.00 | MGLL (0.78) | MGLLALDH1A1MAPTTHRBCNR1 | |
| SCHEMBL4807469 | 0.98 | MGLL (0.81) | MGLLALDH1A1MAPTTHRBCNR1 | |
| SCHEMBL4807460 | 0.98 | MGLL (0.81) | MGLLALDH1A1MAPTTHRBCNR1 | |
| SCHEMBL8704825 | 0.98 | MGLL (0.81) | MGLLALDH1A1MAPTTHRBCNR1 | |
| SCHEMBL11231403 | 0.96 | MGLL (0.76) | MGLLALDH1A1MAPTTHRBCNR1 | |
| SCHEMBL4812727 | 0.96 | MGLL (0.76) | MGLLALDH1A1MAPTTHRBCNR1 | |
| SCHEMBL17685791 | 0.96 | MGLL (0.76) | MGLLALDH1A1MAPTTHRBCNR1 | |
| SCHEMBL8017799 | 0.96 | MGLL (0.76) | MGLLALDH1A1MAPTTHRBCNR1 | |
| SCHEMBL16320538 | 0.96 | MGLL (0.76) | MGLLALDH1A1MAPTTHRBCNR1 | |
| SCHEMBL4812731 | 0.96 | MGLL (0.76) | MGLLALDH1A1MAPTTHRBCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114588055-A | Stable bicontinuous phase cleansing oil and preparation method and application thereof | 中山中研化妆品有限公司 | 2022-06-07 | — | — | CN | claimed |
| US-8425784-B2 | Ozonolysis reactions in liquid CO2 and CO2-expanded solvents | UNIVERSITY OF KANSAS (US) | 2013-04-23 | — | — | US | claimed |
| CN-115501171-B | High-concentration azelaic acid cream and preparation process thereof | 上海丽舒丹医药科技有限公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-114588055-B | Stable bicontinuous phase cleansing oil and preparation method and application thereof | 中山中研化妆品有限公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-3188760-B1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2023-12-06 | — | — | EP | disclosed |
| WO-2023056033-A1 | LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERING CIRCULAR POLYNUCLEOTIDES | ORNA THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| CN-114588055-A | Stable bicontinuous phase cleansing oil and preparation method and application thereof | 中山中研化妆品有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-107072946-B | Lipids and lipid compositions for delivery of active agents | 诺华股份有限公司 | 2022-01-11 | — | — | CN | disclosed |
| US-10844002-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2020-11-24 | — | — | US | disclosed |
| US-10844002-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2020-11-24 | — | — | US | disclosed |
| WO-2020219876-A1 | IONIZABLE AMINE LIPIDS AND LIPID NANOPARTICLES | INTELLIA THERAPEUTICS, INC. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2016037053-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2016-03-10 | — | — | WO | disclosed |
| CN-101909729-B | Ozonolysis reactions in liquid CO2 and CO2-expanded solvents | UNIVERSITY OF KANSAS (US) | 2014-10-22 | — | — | CN | disclosed |
| US-8801939-B2 | Ozonolysis reactions in liquid CO2 and CO2-expanded solvents | UNIVERSITY OF KANSAS (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130240781-A1 | Ozonolysis Reactions in Liquid CO2 and CO2-Expanded Solvents | ARCHER DANIELS MIDLAND COMPANY (US) | 2013-09-19 | — | — | US | disclosed |
| US-8425784-B2 | Ozonolysis reactions in liquid CO2 and CO2-expanded solvents | UNIVERSITY OF KANSAS (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2209547-A2 | OZONOLYSIS REACTIONS IN LIQUID CO2 AND CO2-EXPANDED SOLVENTS | University Of Kansas (US) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009061806-A2 | OZONOLYSIS REACTIONS IN LIQUID CO2 AND CO2-EXPANDED SOLVENTS | UNIVERSITY OF KANSAS (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20090118498-A1 | OZONOLYSIS REACTIONS IN LIQUID CO2 AND CO2-EXPANDED SOLVENTS | ARCHER DANIELS MIDLAND COMPANY | 2009-05-07 | — | — | US | disclosed |
| US-4364743-A | ESTER AND MIDDLE OIL | ERNER WILLIAM E | 1982-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844002-B2 | Lipids and lipid compositions for the delivery of active agents | LRAT, LIPA, LPAR1 | MGLL 89/4885ALDH1A1 1784/4885MAPT 3988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.